XRF Scientific Limited (XRF) AI Stock Analysis

• Market Cap: AU$245.95M
• Dividend Yield: 2.31%
• Average Volume (3M): 240.16K
• Price to Earnings (P/E): 23.5
• Beta (1Y): 0.84
• Revenue Growth: -1.09%
• EPS Growth: 14.88%
• Country: AU
• Employees: N/A
• Sector: Basic Materials
• Sector Strength: 58
• Industry: Hardware, Equipment & Parts
• EPS (TTM): 0.04
• Shares Outstanding: 142,992,370
• 10 Day Avg. Volume: 163,831
• 30 Day Avg. Volume: 240,164
• PEG Ratio: 1.67
• Price to Book (P/B): 4.29
• Price to Sales (P/S): 4.34
• P/FCF Ratio: 30.76
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: AU$2.30
• Price Target Upside: 31.43% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): 0.08
• Revenue Forecast (FY): AU$64.20M

• Rating: 67 Neutral
• Price Target: AU$2.00 ▲(14.29% Upside)
• Action: Reiterated Date: 12/11/25
• Date: Action: Reiterated 12/11/25

XRF Scientific Limited's overall stock score reflects strong financial performance with efficient operations and a solid balance sheet. However, mixed technical indicators and moderate valuation suggest limited growth potential without new catalysts. The absence of earnings call insights and corporate events further limits the score.

Positive Factors

Margin Sustainability

High gross margins (above 40%) and a rising net margin (17.47%) indicate durable pricing power and operational efficiency across equipment, consumables and services. This margin profile supports sustainable cash generation and provides a buffer during cyclical revenue periods over the medium term.

Balance Sheet Strength

A debt-to-equity ratio near 0.073 and a strong equity base give XRF low financial leverage, enhancing resilience to downside scenarios. Conservative capital structure preserves flexibility for targeted investments, maintenance capex or opportunistic M&A without materially increasing solvency risk over the next several months.

Recurring Revenue Model

The business relies on recurring consumables and service revenue tied to laboratory workflows, creating repeat purchase demand and customer stickiness. This recurring element provides predictable, steadier cash flows and revenue visibility than one‑off equipment sales, supporting stability over a 2–6 month horizon.

Negative Factors

Free Cash Flow Decline

A -10.41% drop in free cash flow and FCF sitting slightly below net income reduce the firm's ability to self‑fund growth, dividends or acquisitions. Weaker FCF conversion limits reinvestment flexibility and raises reliance on working capital or external financing if revenue softens.

Top-line Weakness

Reported revenue growth turning negative (-1.05%) signals soft demand in core end markets. Continued top-line contraction would erode operating leverage, make it harder to sustain margin improvements, and necessitate either market share gains or new product/service traction to restore growth.

End-market Cyclicality

Heavy exposure to mining, exploration and lab throughput ties revenue to commodity cycles and capital spending patterns. This structural cyclicality can cause uneven order flows and capital expenditure volatility, complicating planning and potentially amplifying revenue and cash flow swings over the medium term.

XRF Scientific Limited Business Overview & Revenue Model

Company Description

XRF Scientific Limited manufactures and markets precious metal products, specialized chemicals, and instruments for the scientific, analytical, construction material, and mining industries in Australia, Canada, and Europe. It operates through Capital Equipment, Precious Metals, and Consumables segments. The Capital Equipment segment designs, manufactures, and services automated fusion equipment, and high temperature test and production furnaces, as well as general laboratory equipment. The Precious Metals segment manufactures products for the laboratory and platinum alloy markets. The Consumables segment manufactures chemicals and other supplies for analytical laboratories. The company was founded in 1972 and is based in Osborne Park, Australia.

How the Company Makes Money

XRF Scientific generates revenue through several key streams. Primarily, the company earns money from the sale of its XRF instruments, which are used for precise elemental analysis in various industries. This includes both the initial sale of the equipment and ongoing support services, such as maintenance and calibration. Additionally, XRF generates income from consumables, such as sample preparation materials and spare parts, which are essential for the operation of its instruments. The company also benefits from strategic partnerships with industry players and distributors, enhancing its market reach and sales capabilities. Furthermore, XRF may engage in research and development contracts or consultancy services, providing expert knowledge and tailored solutions that contribute to its revenue.

XRF Scientific Limited Financial Statement Overview

Summary

XRF Scientific Limited exhibits strong profitability and a robust balance sheet, with low leverage and efficient operations. However, the recent decline in revenue growth and free cash flow indicates potential challenges in sustaining growth. The company should focus on revitalizing sales and enhancing cash flow management to maintain its financial health.

Income Statement

XRF Scientific Limited demonstrates strong profitability with a consistent gross profit margin above 40% and a net profit margin improving to 17.47% in the latest year. However, the revenue growth rate has turned negative at -1.05%, indicating potential challenges in maintaining sales momentum. Despite this, the company maintains healthy EBIT and EBITDA margins, showcasing operational efficiency.

Balance Sheet

The company maintains a solid balance sheet with a low debt-to-equity ratio of 0.073, indicating prudent leverage management. The equity ratio is strong, reflecting a stable financial structure. However, the return on equity has slightly decreased, suggesting a need for improved profitability or asset utilization.

Cash Flow

XRF Scientific Limited's cash flow performance is mixed, with a decline in free cash flow growth at -10.41%. The operating cash flow to net income ratio is above 1, indicating good cash generation relative to profits. However, the free cash flow to net income ratio is slightly below 1, suggesting room for improvement in cash flow management.

Breakdown	TTM	Jun 2025	Jun 2024	Jun 2023	Jun 2022	Jun 2021
Income Statement
Total Revenue	61.91M	59.45M	59.84M	55.17M	40.01M	31.29M
Gross Profit	30.13M	28.79M	26.27M	22.00M	16.46M	12.89M
EBITDA	16.78M	15.63M	15.32M	13.22M	9.44M	8.05M
Net Income	10.63M	10.38M	8.89M	7.69M	6.08M	5.13M
Balance Sheet
Total Assets	70.03M	72.79M	68.23M	65.55M	55.56M	48.37M
Cash, Cash Equivalents and Short-Term Investments	12.07M	12.23M	12.05M	10.40M	6.65M	5.26M
Total Debt	3.23M	4.41M	3.38M	4.31M	3.51M	1.44M
Total Liabilities	8.67M	12.62M	12.69M	15.97M	12.21M	9.27M
Stockholders Equity	61.36M	60.17M	54.89M	49.25M	43.48M	39.10M
Cash Flow
Free Cash Flow	10.17M	8.39M	6.45M	7.63M	2.63M	3.86M
Operating Cash Flow	12.10M	10.14M	8.09M	8.42M	3.15M	4.51M
Investing Cash Flow	-1.77M	-2.21M	-1.64M	-782.43K	-1.11M	-652.62K
Financing Cash Flow	-6.40M	-7.75M	-4.80M	-3.88M	-648.95K	-2.24M

XRF Scientific Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.75
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:XRF, the sentiment is Negative. The current price of 1.75 is below the 20-day moving average (MA) of 1.90, below the 50-day MA of 2.02, and below the 200-day MA of 1.97, indicating a bearish trend. The MACD of -0.09 indicates Positive momentum. The RSI at 38.37 is Neutral, neither overbought nor oversold. The STOCH value of 30.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:XRF.

XRF Scientific Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
XRF	67 Neutral	AU$245.95M	23.54	18.05%	2.31%	-1.09%	14.88%
Sector *	61 Neutral	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%
KAU	54 Neutral	AU$248.75M	-8.11	-43.66%	―	46.74%	-47.98%
DTR	50 Neutral	AU$1.51B	-88.30	-183.07%	―	―	70.81%
PTN	46 Neutral	AU$128.70M	-3.97	-44.41%	―	―	―
GG8	44 Neutral	AU$340.45M	-86.11	-6.62%	―	―	72.45%
MTM	42 Neutral	AU$534.21M	-9.74	-150.61%	―	―	-186.15%

XRF Scientific Limited Corporate Events

XRF Scientific Seeks ASX Quotation for New Employee Incentive Shares

XRF Scientific Limited has applied for quotation on the ASX of 47,712 ordinary fully paid shares, with an issue date of 4 March 2026. The new securities have been issued under the company’s employee incentive scheme, indicating ongoing use of equity-based remuneration and a minor expansion of its quoted share capital that modestly increases the pool of tradeable shares for investors.

This latest share quotation application reflects routine capital management activity rather than a major strategic shift. For existing shareholders, the incremental dilution is small, while employees participating in the incentive scheme gain additional alignment with the company’s market performance through newly quoted securities.

The most recent analyst rating on (AU:XRF) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on XRF Scientific Limited stock, see the AU:XRF Stock Forecast page.

XRF Scientific Sets Up Direct Operation in India to Target Long-Term Growth

XRF Scientific will establish a new office in India, marking a strategic shift from a distributor-led model to a direct presence in what it views as a key long-term growth market driven by mining and industrial demand. The Indian operation, to begin trading in February under Country Manager Sanjay Mitra with an initial team of five mainly transferred from former distributor San Global Scientific, is expected to deepen penetration of lithium borate fusion sample preparation and other core products, deploy greater resources to expand sales, and bolster customer confidence in the company’s long-term commitment to the rapidly expanding Indian market.

The most recent analyst rating on (AU:XRF) stock is a Buy with a A$2.50 price target. To see the full list of analyst forecasts on XRF Scientific Limited stock, see the AU:XRF Stock Forecast page.